Discover how Medical Affairs teams can create maximum impact by focusing on four key behaviours: proactivity, knowledgeability, commercial astuteness and strong stakeholder connections. Learn how applying the 80/20 rule can drive meaningful value across science and strategy.

Never underestimate it - successfully launching a new medicine into major European markets is a complex and highly fragmented process that requires deep strategic planning and flawless execution. 

Medical departments within biopharma organisations across the world play a vital role in bridging the gap between scientific research and commercial goals. 

Unfortunately, many pharmaceutical organisations struggle to measure or truly appreciate the effectiveness and strategic value of their Medical Affairs teams. 

The role of Medical Affairs within the biopharma industry has undergone significant evolution over the past two decades, but not all of it has been positive.

High-quality medical/marketing collaboration is essential for any successful new medicine launch. When we review where issues stem from, there are three core underlying themes.

The second of a series of articles, containing advice on how to design, develop and deliver Medical Omnichannel solutions.

The first of a series of articles, containing advice on how to design, develop and deliver Medical Omnichannel solutions.

With over ten decades of combined experience in Medical Affairs, read our summary of the key differences and commonalities between MA departments.

Challenging the status quo when it comes to leadership qualities and how best to identify future-leaders in biopharma